Clinical presentation, disease course and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease – a cohort study across sixteen countries **Authors:** CAPACITY-COVID collaborative consortium and LEOSS Study Group* *Authors listed at the end of the manuscript Corresponding author Prof. Dr. Folkert W. Asselbergs E-mail: f.w.asselbergs@umcutrecht.nl Department of Cardiology, Division Heart & Lungs | University Medical Center Utrecht Room E03.511 | P.O. Box 8550 | 3508 GA Utrecht, The Netherlands |

T +31 887555555 | F +31 88755542

2 Aims Patients with cardiac disease are considered high risk for poor outcomes following hospitalization with 3 COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart 4 disease subtypes and in-hospital mortality. 5 6 Method and results We used data from the CAPACITY-COVID registry and LEOSS study. Multivariable 7 modified Poisson regression models were fitted to assess the association between different types of pre-existent 8 heart disease and in-hospital mortality. 10,481 patients with COVID-19 were included (22.4% aged 66 – 75 years; 9 38.7% female) of which 30.5% had a history of cardiac disease. Patients with heart disease were older, 10 predominantly male and more likely to have other comorbid conditions when compared to those without. COVID-11 19 symptoms at presentation did not differ between these groups. Mortality was higher in patients with cardiac 12 disease (30.3%; n=968 versus 15.7%; n=1143). However, following multivariable adjustment this difference was 13 not significant (adjusted risk ratio (aRR) 1.06 [95% CI 0.98 - 1.15, p-value 0.13]). Associations with in-hospital 14 mortality by heart disease subtypes differed considerably, with the strongest association for NYHA III/IV heart 15 failure (aRR 1.43 [95% CI 1.22 – 1.68, p-value <0.001]) and atrial fibrillation (aRR 1.14 [95% CI 1.04 – 1.24, p-16 value 0.01]). None of the other heart disease subtypes, including ischemic heart disease, remained significant after 17 multivariable adjustment. 18 19 Conclusion There is considerable heterogeneity in the strength of association between heart disease subtypes and 20 in-hospital mortality. Of all patients with heart disease, those with severe heart failure are at greatest risk of death 21 when hospitalized with COVID-19. 22 23 **Key words** 24 COVID-19; SARS-CoV-2; epidemiology; patient registry; comorbidity; cardiovascular disease 25 26 27 28 29

1

30

Abstract

Introduction

Coronavirus disease 2019 (COVID-19) has rapidly spread across the globe since December 2019, leading to more than 115 million confirmed cases and 2.5 million fatalities as of the 4th of March 2021.¹ Although the disease is not as lethal (case fatality ratio (CFR) $\sim 0.3 - 1\%$)^{2,3} as the Middle-East respiratory syndrome (MERS; CFR $\sim 35\%$)⁴ and the severe acute respiratory syndrome (SARS; CFR 14 - 15%)⁵, it has become clear that morbidity and mortality is much higher than pandemic influenza (CFR 0.1%)^{6,7}, especially among the elderly³.

Studies show that a significant number of patients who develop severe symptoms of COVID-19 have underlying comorbidities, of which cardiovascular disease (CVD) is reported in 10 – 30% of inpatients in Western-European and American cohorts.⁸⁻¹¹ Patients with pre-existing cardiac disease have consistently been reported to be at increased risk of an unfavorable outcome both among the general population and those requiring hospitalization when compared to patient without these conditions.^{8,12} In one of the largest cohort studies of hospitalized patients thus far (n=20,133), chronic cardiac disease was significantly associated with mortality (adjusted HR 1.16; 95% confidence interval (CI) 1.08 – 1.24).⁸ Another study by Fried et al. (n=11,721) across 38 states in the United States, found an adjusted odds ratio (aOR) of 1.22 (95% CI 1.06 – 1.41) and 1.44 (95% CI 1.27 – 1.63) for mechanical ventilation and death respectively related to cardiac disease.¹¹ The Chinese Center for Disease Control report a CFR five times higher among those with CVD compared to patients without any comorbidities.¹³ These observations are in line with previous studies among patients with influenza and other respiratory tract infections.¹⁴⁻¹⁵

Previous studies have predominantly evaluated the association between having any chronic cardiac disease and COVID-19 related mortality, where all cardiac disease subtypes are analyzed together. 8,11,12 However, from a clinical point of view, it is likely that not all cardiac diseases mediate a similar risk. Increasing our understanding of the clinical course of COVID-19 in patients across different heart disease subtypes is of pivotal importance. Firstly, it can provide guidance for health care professionals in the management of these patients and would better inform shielding guidelines. Secondly, it can bring some clarity for patients, concerned about how their own cardiac disease influences their risk from COVID-19. Reducing these concerns might also have a positive impact on health care seeking behavior during the pandemic, diminishing the detrimental collateral damage the outbreak has provoked in patients with heart disease who are afraid of attending hospitals. 17

The aim of the current study was to investigate whether there is heterogeneity in the strength of association per heart disease subtype and in-hospital mortality. Furthermore, we describe the disease trajectory of

1 COVID-19 in hospitalized patients with- and without pre-existing cardiac disease, from documentation at hospital

admission to discharge or death, including the prevalence of cardiac complications.

Methods

6 Study design and setting

For this study we used data collected in the CAPACITY-COVID registry (www.capacity-covid.eu) and the Lean

Open Survey on SARS-CoV-2 infected patients (LEOSS) study (www.LEOSS.net).

CAPACITY-COVID is a multinational patient registry specifically established to determine the role of CVD in the COVID-19 pandemic (NCT04325412).¹¹8 All adult patients (≥18 years) hospitalized with confirmed or highly suspected COVID-19 are eligible for inclusion in the registry. The extent and scope of inclusion varies per site, depending on local resources and preference. A majority of participating centers (n=54) use a non-selective inclusion, i.e., every adult patient with (highly suspected) COVID-19 or a random sample is included in the registry, and 18 centers applied a selective inclusion of only patients for whom a cardiologist has been consulted, only patients with a history of CVD or cardiovascular risk factors or a selection based on department of admission i.e., only patients admitted to the ward or intensive care unit (ICU). Since the launch of the registry in March 2020, 72 centers across 13 countries have joined the consortium.

Within CAPACITY-COVID, the ISARIC core case report form¹⁹ has been used as the core data set which was extended with ~400 additional variables to capture in-depth information regarding cardiovascular history, the use of cardiovascular medications, cardiac investigations such as ECG and echocardiography and cardiovascular outcomes. The data dictionary is available online (www.capacity-covid.eu). Only data generated during routine clinical care is collected and patients do not undergo any additional investigations for the purpose of this registry. Data is collected in a REDCap database after pseudonymization which is managed by the University Medical Center Utrecht, Utrecht, the Netherlands.

LEOSS is a European multicenter cohort study established in March 2020, collecting information on both hospitalized and ambulant patients with laboratory confirmed COVID-19. A detailed description of the study design has been previously reported.²⁰ In short, patients of all ages can be included in LEOSS. Case collection is anonymized, realized by amongst other the absence of any variables containing directly identifying information in the case report form, only a small subset of variables associated with a high risk of re-identification and the categorized collection of continuous variables (such as age).²¹ Currently centers from Belgium, France, Germany,

Latvia, Italy, Spain, Switzerland and Turkey contribute data to the registry. The data collection is coordinated by

the University Hospital of Cologne in Germany.

3

4

1

2

- Study population
- 5 We excluded patients only treated in an ambulatory setting, children (age <18 years) and patients for which the 6 region of inclusion, COVID-19 status, admission date, history of cardiac disease, age, sex or outcome were 7 unconfirmed. All hospitalized patients aged >18 years with a laboratory confirmed SARS-CoV-2 infection 8 registered between March and November 2020 were included. A list of all participating sites that contributed with 9 data to the current study is provided in Table S1. The informed consent procedure varied per study site, following 10 local and national rules and regulations during the pandemic. Within CAPACITY-COVID, a majority of 11 participating sites handled an opt-out approach, where patients received written information during or after 12 hospital admission. For sites in the UK, informed consent was not required under emergency legislation during

the pandemic. Inclusion into LEOSS did not require informed consent due to anonymous case collection. Medical

14 ethics approval was obtained nationally or independently for each participating site complying with the

Declaration of Helsinki.

16

17

27

28

29

30

15

13

- Statistical analysis
- 18 Continuous variables in CAPACITY-COVID were categorized to align with LEOSS prior to merging the datasets 19 from these two different sources. Multiple imputation (R package mice) was performed to deal with missingness 20 across baseline variables required for the regression models through the generation of 10 imputed datasets. The 21 following variables were included in the multiple imputation model: all variables indicated with an asterisk in 22 Table 1-3, and furthermore presence of pre-existing cardiac disease, arrhythmia/conduction disorder, heart 23 failure, coronary artery disease (CAD), valvular heart disease, extent of inclusion (all/random sample vs. selected 24 inclusion as described above), cohort (CAPACITY-COVID vs. LEOSS) and region of inclusion (United 25 Kingdom, Netherlands/Belgium, Germany/Switzerland, Middle - East and Southern-Europe). Baseline variables 26 with >40% missingness were excluded from further analysis.

For the main analyses, multivariable modified Poisson models with robust standard errors were used to estimate the association between a history of cardiac disease and in-hospital mortality across the pooled ten imputed datasets. Heterogeneity in associations was also determined across various clinically relevant subgroups including age (\leq 65 and \geq 65), sex, body mass index (BMI) (\leq 30 and \geq 30), diabetes, hypertension, chronic kidney

disease (CKD) and chronic obstructive pulmonary disease (COPD). In the secondary analyses, associations between pre-defined specific types of heart disease and the in-hospital mortality were determined. The following heart disease subtypes were analyzed: arrhythmias/conduction disorders, CAD, myocardial infarction (MI), heart failure and valvular heart disease. To be able to determine differences in the association between the pre-defined cardiac disease subtypes and in-hospital mortality in adults versus the elderly, analyses were also performed in patients \leq 65 years and \geq 65 years. The cut-off was set at 65 since most COVID-19 vaccination strategies in Europe have defined the elderly as those \geq 65 years of age.²²

All analyses were adjusted for the following covariates: age, sex, BMI, diabetes, hypertension, CKD, COPD and geographic region of inclusion (see above). For the sensitivity analyses we excluded patients included by centers handling a selective inclusion strategy as previously outlined. In addition, we assessed the direction and magnitude of the associations based on registry of inclusion (CAPACITY vs. LEOSS), next to fitting models in the dataset of the combined cohorts.

Logistic regression on the non-imputed dataset was used to identify association of the most prevalent COVID-19 symptoms at presentation and eight different age categories in the total cohort and after stratification on pre-existent cardiac disease. Due to low numbers of young patients with a history of cardiac disease, the four lowest age categories were merged in the stratified analyses (18 - 55 years).

Results of the modified Poisson regression models are reported as risk ratios (RR) with 95% confidence intervals (CI)) and the logistic regression models as odds ratios (ORs) with 95% CI's. Statistical significance was set at an alpha of 5% and all hypothesis tests were two-sided. Continuous variables were summarized as means (SD) or medians [IQR] and categorical variables as counts (%). All analyses were performed in R Studio (version 1.3.959, Vienna, Austria).

Results

Baseline characteristics

In total, 13,176 patients had been included in CAPACITY-COVID or LEOSS between March and of November 2020. After applying exclusion criteria, 10,481 patients from sixteen countries were retained for the final analysis

(Figure S1). Baseline characteristics stratified by the presence of pre-existing cardiac disease and age are

summarized in Table 1.

The majority of patients were aged between 66 – 75 (n=2,346; 22.4%), and more than half the cohort was composed of individuals >65 years (n=5,466; 52.2%). Most patients were white (n=7,606; 83.1%), predominantly male (n=6,430; 61.3%), and 45.3% (n=4,748) had a BMI >25 kg/m². At baseline, almost one third of patients (n=3,195; 30.5%) had pre-existing heart disease of which CAD (n=1589; 15.2%) and cardiac arrhythmias/conduction disorders (n=1,557; 14.9%) were most common (**Table S2**). In total, 762 patients (7.4%) had been previously diagnosed with heart failure. Other frequent major comorbidities were diabetes (n=2,482; 24.0%) and CKD (n=1,274; 12.3%).

Compared to patients without a history of cardiac disease, patients with pre-existing heart disease were generally older, more often male (65.9% vs. 59.4%) and had a higher burden of cardiovascular risk factors and other comorbid conditions at baseline (**Table 1**). Detailed phenotyping of underlying pre-existing cardiac diseases of patients registered in CAPACITY-COVID, including arrhythmias, conduction disorders, type of ischemic- and valvular heart disease are outlined in **Table S3**. To evaluate heterogeneity across datasets, baseline characteristics were also stratified by the cohort of origin (CAPACITY-COVID vs. LEOSS; **Table S2**). Patients in LEOSS tended to be younger with an overall lower prevalence of heart disease.

Complaints at admission

The median duration from the onset of symptoms to hospital admission was 6 days [IQR 2 – 9]. Fever, cough and shortness of breath were the most common symptoms at presentation reported in 60.3%, 56.4% and 52.6% of patients respectively (**Table 2**). The odds of having these symptoms varied across age, with fever, cough and dyspnea being reported less frequently in the younger (<45 years) and older (>65 years) age groups (**Figure S2**). The probability of experiencing a sore throat, anosmia and chest pain declined with age, while fatigue was reported more often with increasing age. Heterogeneity in complaints and vital signs at admission was also assessed by stratification by cohort of inclusion (CAPACITY-COVID vs. LEOSS; **Table S4**). Of symptoms overlapping with CVD, chest pain was most common, reported by 8.3% of patients. Less than five percent of patients experienced (pre) syncope, palpitations, orthopnea or peripheral edema (**Table S4**). After stratification by age, the pattern of complaints did not differ between patients with and without a history of cardiac disease (**Figure S3**).

Outcomes

The median duration of hospital admission was 9 [5-19] days (**Table 3**). More than one in four patients were admitted to a critical care unit (n=2655; 25.3%) with a median length of stay of 13 [6-24] days. The proportion

of patients admitted to a critical care unit increased with age until 75 years. Patients aged >75 years were predominantly treated on the ward (**Table S5**). Overall, the comorbidity burden among patients on a critical care unit was lower than for patients admitted to the ward only (**Table S5**). Patients that were admitted to a critical care unit tended to be more ill at admission based on vitals and laboratory values at hospital admission (**Table S6**). During their hospital admission 20.1% (n=2111) of patients died. Mortality was strongly related to age, with a mortality of 2% (n=3) in patients aged 18-25 years and 41.6% (n=363) in patients aged >85 years (**Table S7**). Oxygen saturation levels were lower at admission in those who died, while the levels of inflammatory markers (C-reactive protein and total white blood cell count) were higher (**Table S8**). In patients with cardiac disease 30.3% (n=968) died during their hospital admission versus 15.7% (n=1143) in patients without chronic heart disease (**Table 3**). In addition to heart disease, other comorbidities were also more prevalent in patients that died during their hospital admission (**Table S7**).

Cardiac and thromboembolic complications

During hospitalization, serious cardiac complications including myocarditis, MI and new onset heart failure were diagnosed in 0.3% (n=28), 0.6% (n=60) and 1.2% (n=115) of patients respectively (**Table 3**). Other serious cardiac complications registered only in CAPACITY-COVID, including malignant ventricular arrhythmias, endocarditis and pericarditis were also uncommonly diagnosed (<1% of patients; **Table S9**). MI and new onset heart failure was diagnosed more frequently in patients with pre-existing cardiac disease compared to those without (**Table 3**). Among thromboembolic complications, pulmonary embolism was most prevalent being diagnosed in 4.2% (n=420) of patients (**Table 3**). All complications occurred more often in patients admitted to a critical care unit and patients that died in-hospital (**Table S10, S11**), with the difference being most pronounced for pulmonary embolism, which was diagnosed >10 times as often in the critically ill. Venous thromboembolic complications were diagnosed less frequently among patients with a history of heart disease (**Table 3**).

Association between prior history of cardiac disease and in-hospital mortality

The multivariable modified Poisson regression model fitted in the total population yielded a non-statistically significant association between any pre-existing cardiac disease and in-hospital mortality (aRR 1.06 [95% CI 0.98 1.15, p-value 0.13])(**Figure 1**). This association was further explored across different clinically relevant subgroups (**Table S12**). Apart from age (p-value interaction 0.03), the subgroup analyses did not reveal any significant

1 interactions with prior heart disease. Furthermore, sensitivity analyses by the exclusion of patients included from

centers that handled a selective inclusion (n=759) did not yield any different results (**Table S13**).

Association between different pre-existing cardiac comorbidities and in-hospital mortality

To assess heterogeneity in the associations between different types of heart disease and hospital mortality, modified Poisson regression models were fitted for all pre-specified cardiac disease subgroups. After multivariable adjustment, the strongest association was found for NYHA III/IV heart failure and in-hospital mortality (aRR 1.43 [95% CI 1.22 – 1.68, p-value <0.001](**Figure 1**). Also, atrial fibrillation was found to be significantly associated with in-hospital mortality (aRR 1.14 [95% CI 1.04 – 1.24], p-value 0.01). For the other

heart disease subtypes, including ischaemic heart disease, no significant associations were found (Figure 1, Table

S14).

Since the elderly (>65 years) and adults with comorbidities are defined as two of the main risk groups being prioritized in ongoing vaccination campaigns and statistical interaction was established between pre-existing cardiac disease and age, associations between the various heart disease subtypes and in-hospital mortality were also determined in patients ≤65 years and >65 years (**Figure 2**). For myocardial infarction and NYHA III/IV the interaction with age was significant (p-value 0.02). The difference was most pronounced for the association between NYHA III/IV and in-hospital mortality with an aRR of 2.67 ([95% CI 1.30 − 5.50] p-value 0.01) in patients aged ≤65 years vs.1.42 ([95% CI 1.21 − 1.66] p-value <0.001) in patients aged >65 years.

Discussion

A large proportion of patients developing severe COVID-19 have underlying CVD. The aim of this study was to describe and compare the disease course and outcomes in hospitalized COVID-19 patients with and without pre-existing cardiac disease. The most important findings of this work are (i) the symptoms of COVID-19 at presentation are age dependent and do not differ in individuals with and without prior cardiac disease (ii) serious incident cardiac complications are diagnosed infrequently during hospitalization and are seen more often in patients with known cardiac disease at baseline (iii) the association between prior heart disease and in-hospital mortality varies across heart disease subtypes where (iv) severe heart failure (NYHA III/IV) associates most strongly with in-hospital mortality followed by (v) atrial fibrillation and (vi) there was no association with ischemic heart disease.

In line with others²³, we found that COVID-19 symptoms at admission vary mainly with age with no evidence that prior cardiac disease influences this relationship or the symptoms. Typical symptoms of COVID-19 including fever, cough and shortness of breath, were reported less often in the elderly. Overall complaints mimicking cardiac disease, such as chest pain, palpitations and orthopnea were reported by only a minority of patients (<10%). In this regard, it is interesting that cardiac-like symptoms such as chest pain and palpitations have been reported by 17-44% and 20-32% of patients in the 2-3 months after the active infection as part of the so-called "long COVID" syndrome. 24-27 Whether these complaints are related to cardiovascular involvement in the convalescent phase of the disease or should predominantly be viewed as an epiphenomenon remains unclear. According to our study, serious cardiac complications are rarely diagnosed during hospitalization with COVID-19, with a prevalence <2% of patients. To aid interpretation of these numbers it is of interest to relate them to the occurrence of cardiac complications in patients hospitalized for other (viral) infectious diseases. A recent large French retrospective cohort study found that the prevalence of MI and atrial fibrillation was lower in patients with COVID-19 than seasonal influenza with a prevalence of 0.6% vs. 1.1% and 12.4% vs. 15.8% respectively. Unfortunately, this study did not report the prevalence of any other cardiac complications, including heart failure and myocarditis. As cardiomyocytes express ACE2^{28,29}, the docking receptor of SARS-CoV-2, it has been speculated that SARS-CoV-2 may infect cardiomyocytes, replicate in cardiac tissue and thereby induce direct myocardial damage. These concerns have also been triggered by the finding that raised levels of troponin above test-specific upper limits are found in up to one third of patients at hospital admission.^{30,31} Histopathological studies of myocardial tissue in the setting of COVID-19 have been scarce up to this point. A literature review evaluating findings of 22 studies across 277 post-mortem examinations, found evidence for myocarditis in <2%.32 This finding contrasts the results of a number of cardiac magnetic resonance (CMR) studies evaluating tissue characteristics and function 2 – 3 months after an established SARS-CoV-2 infection. ^{27,33-35} In the largest study by Kotecha et al. among 148 patients that had a troponin elevation during hospitalization, non-ischemic myocarditis-like late gadolinium enhancement was found in 26% of patients with one-third showing signs of active myocarditis.³⁴ These findings were not associated with left ventricular dysfunction. In CMR studies conducted predominantly among clinically recovered mildly symptomatic or asymptomatic cases, up to 60% were described to have raised native T2 times, and which the authors suggested might be due to ongoing myocardial inflammation.^{27,35} Whether these CMR findings are unique to patients that have been infected with SARS-CoV-

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

2, or also are seen in other (viral) infectious diseases has been poorly investigated. Evidence of a clear causal

relationship between SARS-CoV-2 and myocarditis thereby still remains elusive. It can be speculated that most

patients may have troponin elevations secondary to profound hypoxia and a supply/demand imbalance rather than direct damage due to viral invasion in cardiac tissue.³¹ However, the discrepancy in the limited number of patients diagnosed with cardiac complications during hospitalization and the significant proportion of patients with abnormal findings in imaging studies is a concern and warrants further investigation. Cardiac complications may have been missed, due to the overlapping symptomatology with COVID-19 as well as limited access or performed diagnostic tests.

Contrary to cardiac complications, which in our study were rarely diagnosed during hospitalization, venous thrombosis and thromboembolism are common features of COVID-19, with a prevalence 3-4 times higher when compared to seasonal influenza.⁷ Thromboembolic events are especially common in patients admitted to the ICU, with pulmonary embolism being diagnosed more than 10 times as often (12.6% vs. 1.2%) in our cohort compared to patients treated on the ward only. The prevalence of pulmonary embolism in the ICU population in our study is lower than in studies based on data originating from patients hospitalized in the first months of the pandemic, that reported a prevalence of up to 20.6%. ^{36,37} This discrepancy most likely reflects the implementation of enhanced antithrombotic prophylactic strategies in patients admitted with COVID-19 during the course of 2020. Interestingly, we observed that thromboembolic complications were less common among patients known with cardiac disease in our cohort. This observation is possibly related to pre-admission use of anticoagulants for the treatment of pre-existing cardiac conditions. This will be explored in ongoing analyses.

Among different heart disease subtypes, severe heart failure (NYHA class III/IV) was most strongly associated with in-hospital mortality in this study across the spectrum of different heart disease subtypes. Others have also identified patients with heart failure as one of the groups at particular risk. 38,39 Among 6,439 hospitalized patients, in-hospital mortality was significantly higher among patients with a history of heart failure (aOR 1.88 [95% CI 1.27 – 2.78]). Similar findings were reported by the Tomasoni et al. (n=692) with a crude HR of 2.43 [95% CI 1.69 – 3.50] for heart failure remaining significant after adjustment for age, sex, various comorbidities and vitals and laboratory values at admission (adjusted HR 2.25 [95% CI 1.26 – 4.02]. Whether the absolute risk of being hospitalized in the presence of heart failure is also increased was recently investigated in a population-based study, which found an aOR of 4.43 (95% CI 2.59 – 8.04; p-value <0.001). Besides age and male sex, heart failure had the strongest association with in-hospital mortality among various different comorbidities in this study.

Apart from advanced heart failure, we also observed an independent association between pre-existing atrial fibrillation and in-hospital mortality. Previous studies have predominantly focused on the impact of atrial fibrillation occurring during hospitalization in patients with COVID-19. Mountantonakis et al. evaluated the

incremental effect of new-onset atrial fibrillation with a history of atrial fibrillation on in-hospital mortality and found an aRR of 1.18 [95% CI 1.04 - 1.33]. Whether pre-existing atrial fibrillation should be viewed as an independent risk factor of in-hospital mortality or is primarily a proxy for underlying frailty in the elderly remains to be explored.

Importantly, besides severe heart failure and atrial fibrillation, none of the other types of heart disease were associated with in-hospital mortality after adjustment for age, sex, BMI, diabetes, hypertension, CKD and COPD. This heterogeneity was also evident in the population based study by Petrilli et al. in which patients with CAD did not seem to be at increased risk of hospitalization due to COVID-19 (aOR was 1.08; 95% CI 0.81 – 1.44; p-value 0.60).⁴⁰ It could therefore be questioned whether all patients with heart disease should be defined as a group at risk, certainly when viewed in context of other demographic factors such as age and sex, as these appear to contribute to COVID-19 outcome to a much larger extent than pre-existing cardiac disease.¹²

As heart failure and atrial fibrillation are primarily diseases of the elderly, with a steep increase in the prevalence as well as severity beyond the age of 75 years 42-44, it is likely that a majority of patients with the heart disease subtypes associated with the highest risk as identified in this study will be among the first to be vaccinated according to current vaccine rollout strategies across Europe. Adults with comorbidities are identified as an additional priority group but current advice lacks detail on which comorbidities should be considered high-risk. Therefore, we also determined the strength per heart disease subtype and in-hospital mortality in patients <65 years. Due to the lower comorbidity burden in this group, we hypothesized that the associations for the different types of heart disease would be higher in this patient population. For myocardial infarction and NYHA III/IV we found a significant interaction with age, with an aRR that was higher in patients ≤65 years. However, we lacked sufficient power to draw any strong conclusions from this finding.

Limitations

Our study determines associations on a population level (e.g., all patients with heart failure) rather than individual risks and is limited to patients with COVID-19 that were hospitalized. In some countries that provided data, hospitalization and potentially life-sustaining treatments such as mechanical ventilation, might have been withheld in those with high frailty, including those with severe heart failure, which may have led to an overestimation of the found associations. Furthermore, we could not reliably investigate associations between heart disease subtypes and HDU/ICU admission since we observed that patients admitted to a critical care unit were overall younger with fewer comorbidities. Since age in particular is well-known to be associated with a more severe COVID-19

disease course, this difference in baseline characteristics in those admitted to HDU/ICU is suggestive of an underlying selection of patients admitted for critical care. The mechanisms behind this selection are likely complex, influenced by amongst others the variability in critical care bed numbers across participating countries and available staff that may have led to demand for life-saving resources (nearly) exceeding supply, patient preference as well as cultural differences in clinical decision making. A further study limitation is that we only examined the impact of pre-existing CVD on in-hospital mortality, which excludes the many deaths that have occurred in community settings and nursing homes. Finally, there was no central adjudication of events in either of the two registries. Moreover, echocardiographic data, providing more in-depth insight into heart failure etiology as well as the degree of systolic and diastolic dysfunction prior to hospitalization are lacking.

Future perspectives

With approvals of the first vaccines for COVID-19 there is finally hope of starting the containment of COVID-19 during 2021. During the first year of the pandemic, the scientific community has improved the understanding of this new disease considerably, including its effects on the cardiovascular system. However, many aspects are still unknown. Evidence for a strong causal relationship between SARS-CoV-2 and myocarditis is still lacking. The discrepancy between the low prevalence of clinically diagnosed cardiac complications among the most ill requiring hospitalization and the large proportion of only mildly or even asymptomatic patients with abnormal findings on CMR after the acute phase of the disease has ceased warrant further investigation to understand their specificity and significance. In addition, studies on the long-term incidence of major adverse cardiac events (MACE) are required. Future studies should also evaluate the added value of different pre-existing cardiac comorbidities such as severe heart failure in prognostic models. Lastly, considering the high incidence of (venous) thromboembolic events, the results of randomized controlled trials regarding the optimal antithrombotic prophylactic strategy are much awaited.

Conclusion

In this large retrospective cohort study across sixteen countries, more than one in three patients hospitalized with COVID-19 had underlying chronic cardiac disease. Patients with a history of heart disease were older, more frequently male and had a higher burden of other comorbid conditions at baseline. Inherently, patients with a history of heart disease have a poorer outcome once infected with SARS-CoV-2. However, after multivariable adjustment we did not find a significant association between chronic heart disease and in-hospital mortality. When

1 evaluating the associations between specific heart disease subtypes and in-hospital mortality, considerable

heterogeneity was detected. Of all patients with heart disease, those with severe heart failure are at greatest risk

of death when hospitalized with COVID-19.

Funding

6 This work was supported by the Dutch Heart Foundation, as a National Institute for Health Research

(NIHR)/British Heart Foundation COVID-19 Flagship research programme, the EuroQol Research Foundation,

Novartis Global, Amgen Europe, Novo Nordisk Nederland, Servier Nederland and Daiichi Sankyo Nederland

(CAPACITY-COVID) and the German Centre for Infection Research (DZIF) and the Willy Robert Pitzer

Foundation (LEOSS).

Marijke Linschoten is supported by the Alexandre Suerman Stipend of the University Medical Center Utrecht. Folkert W. Asselbergs is supported by CardioVasculair Onderzoek Nederland 2015-12 eDETECT and along with Bryan Williams supported by the NIHR University College London Hospitals Biomedical Research Centre. Fleur V. Y. Tjong is supported by the NWO Rubicon grant 452019308, the Amsterdam Cardiovascular Institute MD/PhD Grant 2019-2020 and Postdoc Grant 2020. The work of Philippe Kopylov and Daria Gognieva was financed by the Ministry of Science and Higher Education of the Russian Federation within the framework of state support for the creation and development of World-Class Research Center Digital biodesign and personalized healthcare no. 057-15-2020-926.

Acknowledgements

We want to express our gratitude and appreciation to all participating sites and researchers part of the CAPACITY-COVID collaborative consortium and LEOSS study and all research professionals that have contributed to the data collection. CAPACITY-COVID gratefully acknowledges the following organizations for their assistance in the development of the registry and/or coordination regarding the data registration in the collaborating centers: partners of the Dutch CardioVascular Alliance (DCVA), the Dutch Association of Medical Specialists (FMS) and the British Heart Foundation Centres of Research Excellence. In addition, the consortium is thankful for the endorsement of the CAPACITY-COVID initiative by the European Society of Cardiology (ESC), the European Heart Network (EHN) and the Society for Cardiovascular Magnetic Resonance (SCMR). Part of this work is supported by the BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 joint undertaking under grant agreement no 116074. This joint undertaking receives support from the EU's Horizon 2020 research

- 1 and innovation programme and EFPIA. Furthermore we want to thank the LEOSS study infrastructure group:
- 2 Jörg Janne Vehreschild (Goethe University Frankfurt, University Hospital of Cologne), Lisa Pilgram (Goethe
- 3 University Frankfurt), Carolin E. M. Jakob (University Hospital of Cologne), Melanie Stecher (University
- 4 Hospital of Cologne), Max Schons (University Hospital of Cologne), Susana M. Nunes de Miranda (University
- 5 Hospital of Cologne), Annika Claßen (University Hospital of Cologne), Sandra Fuhrmann (University Hospital
- 6 of Cologne), Bernd Franke (University Hospital of Cologne), Nick Schulze (University Hospital of Cologne),
- 7 Fabian Praßer (Charité, Universitätsmedizin Berlin) and Martin Lablans (University Medical Center Mannheim).

8

9

References

- 1. Johns Hopkins Coronavirus Research Center: https://coronavirus.jhu.edu/map.html (4 March 2021).
- 2. Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, Saemundsdottir J,
- 12 Sigurdsson A, Sulem P, Agustsdottir AB, Eiriksdottir B, Fridriksdottir R, Gardarsdottir EE, Georgsson
- G, Gretarsdottir OS, Gudmundsson KR, Gunnarsdottir TR, Gylfason A, Holm H, Jensson BO,
- Jonasdottir A, Jonsson F, Josefsdottir KS, Kristjansson T, Magnusdottir DN, le Roux L, Sigmundsdottir
- G, Sveinbjornsson G, Sveinsdottir KE, Sveinsdottir M, Thorarensen EA, Thorbjornsson B, Löve A,
- Masson G, Jonsdottir I, Möller AD, Gudnason T, Kristinsson KG, Thorsteinsdottir U, Stefansson K.
- 17 Spread of SARS-CoV-2 in the Icelandic Population. N Engl J Med. 2020;382(24):2302-2315. doi:
- 18 10.1056/NEJMoa2006100.
- 19 3. Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, Storgaard M, Al Khalili S,
- 20 Simonsen L. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis.
- 21 2020;20(9):e238-e244. doi: 10.1016/S1473-3099(20)30484-9.
- 4. WHO Middle East respiratory syndrome coronavirus (MERS-CoV): key facts.
- 23 https://www.who.int/en/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus-
- 24 (mers-cov) Date: March 11, 2019. (3 September 2020).
- 5. WHO Update 49—SARS case fatality ratio, incubation period.
- 26 https://www.who.int/csr/sars/archive/2003 05 07a/en/ Date: May 7, 2003. (3 September 2020).
- 6. Ruan S. Likelihood of survival of coronavirus disease 2019. Lancet Infect Dis. 2020;20(6):630-631. doi:
- 28 10.1016/\$1473-3099(20)30257-7.
- 7. Piroth L, Cottenet J, Mariet AS, Bonniaud P, Blot M, Tubert-Bitter P, Quantin C. Comparison of the
- 30 characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-

- based retrospective cohort study. Lancet Respir Med. 2020;9(3):251-9. doi: 10.1016/S2213-
- 2 2600(20)30527-0.
- 8. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM,
- 4 Dondelinger F, Carson G, Merson L, Lee J, Plotkin D, Sigfrid L, Halpin S, Jackson C, Gamble C, Horby
- 5 PW, Nguyen-Van-Tam JS, Ho A, Russell CD, Dunning J, Openshaw PJ, Baillie JK, Semple MG;
- 6 ISARIC4C investigators. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC
- WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ.
- 8 2020;369:m1985. doi: 10.1136/bmj.m1985.
- 9. Linschoten M, Peters S, van Smeden M, Jewbali LS, Schaap J, Siebelink HM, Smits PC, Tieleman RG,
- van der Harst P, van Gilst WH, Asselbergs FW; CAPACITY-COVID collaborative consortium. Cardiac
- 11 complications in patients hospitalised with COVID-19. Eur Heart J Acute Cardiovasc Care.
- 12 2020;9(8):817-823. doi: 10.1177/2048872620974605.
- 13 10. Yehia BR, Winegar A, Fogel R, Fakih M, Ottenbacher A, Jesser C, Bufalino A, Huang RH, Cacchione
- J. Association of Race With Mortality Among Patients Hospitalized With Coronavirus Disease 2019
- 15 (COVID-19) at 92 US Hospitals. JAMA Netw Open. 2020;3(8):e2018039. doi:
- 16 10.1001/jamanetworkopen.2020.18039.
- 17 11. Fried MW, Crawford JM, Mospan AR, Watkins SE, Munoz Hernandez B, Zink RC, Elliott S, Burleson
- 18 K, Landis C, Reddy KR, Brown RS. Patient Characteristics and Outcomes of 11,721 Patients with
- 19 COVID19 Hospitalized Across the United States. Clin Infect Dis. 2020:ciaa1268. doi:
- 20 10.1093/cid/ciaa1268. Epub ahead of print.
- 21 12. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans
- D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas IJ, Rentsch CT, Mathur
- R, Wong AYS, Grieve R, Harrison D, Forbes H, Schultze A, Croker R, Parry J, Hester F, Harper S,
- Perera R, Evans SJW, Smeeth L, Goldacre B. Factors associated with COVID-19-related death using
- 25 OpenSAFELY. Nature. 2020;584(7821):430-436. doi: 10.1038/s41586-020-2521-4.
- 26 13. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019
- 27 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for
- 28 Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. doi: 10.1001/jama.2020.2648.

- 1 14. Weng TC, Chiu HR, Chen SY, Shih FY, King CC, Fang CC. National retrospective cohort study to
- 2 identify age-specific fatality risks of comorbidities among hospitalised patients with influenza-like
- 3 illness in Taiwan. BMJ Open. 2019;9(6):e025276. doi: 10.1136/bmjopen-2018-025276.
- 4 15. Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, Fadel SA, Tran D, Fernandez E,
- 5 Bhatnagar N, Loeb M. Populations at risk for severe or complicated influenza illness: systematic review
- 6 and meta-analysis. BMJ. 2013;347:f5061. doi: 10.1136/bmj.f5061.
- 7 16. Siropaides CH, Sulistio MS, Reimold SC. Crucial Conversations With Patients in the Era of COVID-19.
- 8 Circulation. 2020;142(3):191-193. doi: 10.1161/CIRCULATIONAHA.120.047374. Epub 2020 May 6.
- 9 17. Mafham MM, Spata E, Goldacre R, Gair D, Curnow P, Bray M, Hollings S, Roebuck C, Gale CP, Mamas
- MA, Deanfield JE, de Belder MA, Luescher TF, Denwood T, Landray MJ, Emberson JR, Collins R,
- Morris EJA, Casadei B, Baigent C. COVID-19 pandemic and admission rates for and management of
- 12 acute coronary syndromes in England. Lancet. 2020;396(10248):381-389. doi: 10.1016/S0140-
- 13 6736(20)31356-8.
- 18. Linschoten M, Asselbergs FW. CAPACITY-COVID: a European Registry to determine the role of
- 15 cardiovascular disease in the COVID-19 pandemic. Eur Heart J. 2020;41(19):1795-1796. doi:
- 16 10.1093/eurheartj/ehaa280.
- 19. ISARIC COVID-19 CRF. https://isaric.org/research/covid-19-clinical-research-resources/covid-19-crf/
- 18 (16 of February 2021).
- 19 20. Jakob CEM, Borgmann S, Duygu F, Behrends U, Hower M, Merle U, Friedrichs A, Tometten L, Hanses
- F, Jung N, Rieg S, Wille K, Grüner B, Klinker H, Gersbacher-Runge N, Hellwig K, Eberwein L, Dolff
- S, Rauschning D, von Bergwelt-Baildon M, Lanznaster J, Strauß R, Trauth J, de With K, Ruethrich M,
- Lueck C, Nattermann J, Tscharntke L, Pilgram L, Fuhrmann S, Classen A, Stecher M, Schons M, Spinner
- C, Vehreschild JJ. First results of the "Lean European Open Survey on SARS-CoV-2-Infected Patients
- 24 (LEOSS)". Infection. 2021 Feb;49(1):63-73. doi: 10.1007/s15010-020-01499-0.
- 25 21. Jakob CEM, Kohlmayer F, Meurers T, Vehreschild JJ, Prasser F. Design and evaluation of a data
- anonymization pipeline to promote Open Science on COVID-19. Sci Data. 2020 Dec 10;7(1):435. doi:
- 27 10.1038/s41597-020-00773-y.
- 28 22. European Centre for Disease Prevention and Control. Overview of COVID-19 vaccination strategies and
- vaccine deployment plans in the EU/EEA and the UK 2 December 2020. ECDC: Stockholm; 2020.

- 1 23. Pritchard MG, ISARIC Clinical Characterisation Group. COVID-19 symptoms at hospital admission
- 2 vary with age and sex: ISARIC multinational study.
- 3 medRxiv 2020.10.26.20219519; doi:https://doi.org/10.1101/2020.10.26.20219519
- 4 24. Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens D, Hastie C, O'Hara M, Suet JC, Burls A,
- 5 Foote C, Carson G, Olliaro P, Sigfrid L, Stavropoulou C. Characterising long-term covid-19: a rapid
- 6 living systematic review.
- 7 medRxiv 2020.12.08.20246025; doi:https://doi.org/10.1101/2020.12.08.20246025
- 8 25. Carfi A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent
- 9 Symptoms in Patients After Acute COVID-19. JAMA. 2020;324(6):603-605. doi:
- 10 10.1001/jama.2020.12603.
- 11 26. Goërtz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, Houben-Wilke S,
- Burtin C, Posthuma R, Franssen FME, van Loon N, Hajian B, Spies Y, Vijlbrief H, van 't Hul AJ, Janssen
- DJA, Spruit MA. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19
- 14 syndrome? ERJ Open Res. 2020;6(4):00542-2020. doi: 10.1183/23120541.00542-2020.
- 27. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, Shchendrygina A, Escher F,
- Vasa-Nicotera M, Zeiher AM, Vehreschild M, Nagel E. Outcomes of Cardiovascular Magnetic
- 17 Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19).
- 18 JAMA Cardiol. 2020;5(11):1265-1273. doi: 10.1001/jamacardio.2020.3557. Erratum in: JAMA Cardiol.
- 19 2020;5(11):1308.
- 28. Nicin L, Abplanalp WT, Mellentin H, Kattih B, Tombor L, John D, Schmitto JD, Heineke J, Emrich F,
- Arsalan M, Holubec T, Walther T, Zeiher AM, Dimmeler S. Cell type-specific expression of the putative
- 22 SARS-CoV-2 receptor ACE2 in human hearts. Eur Heart J. 2020;41(19):1804-1806. doi:
- 23 10.1093/eurheartj/ehaa311.
- 24 29. The Human Protein Atlas: https://www.proteinatlas.org/ENSG00000130234-ACE2/celltype (23
- 25 February 2021)
- 30. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell
- 27 COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J,
- 28 Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG,
- Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP.
- Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With

- 1 COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-2059. doi: 10.1001/jama.2020.6775.
- 2 Erratum in: JAMA. 2020;323(20):2098.
- 3 31. Lala A, Johnson KW, Januzzi JL, Russak AJ, Paranjpe I, Richter F, Zhao S, Somani S, Van Vleck T,
- 4 Vaid A, Chaudhry F, De Freitas JK, Fayad ZA, Pinney SP, Levin M, Charney A, Bagiella E, Narula J,
- 5 Glicksberg BS, Nadkarni G, Mancini DM, Fuster V; Mount Sinai COVID Informatics Center. Prevalence
- 6 and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. J Am Coll Cardiol.
- 7 2020 Aug 4;76(5):533-546. doi: 10.1016/j.jacc.2020.06.007. Epub 2020 Jun 8.
- 8 32. Halushka MK, Vander Heide RS. Myocarditis is rare in COVID-19 autopsies: cardiovascular findings
- 9 across 277 postmortem examinations. Cardiovasc Pathol. 2021;50:107300. doi:
- 10 10.1016/j.carpath.2020.107300.
- 11 33. Huang L, Zhao P, Tang D, Zhu T, Han R, Zhan C, Liu W, Zeng H, Tao Q, Xia L. Cardiac Involvement
- 12 in Patients Recovered From COVID-2019 Identified Using Magnetic Resonance Imaging. JACC
- Cardiovasc Imaging. 2020;13(11):2330-2339. doi: 10.1016/j.jcmg.2020.05.004.
- 14 34. Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalesvaran K, Thornton G, Patel R, Chacko L, Brown JT,
- 15 Coyle C, Leith D, Shetye A, Ariff B, Bell R, Captur G, Coleman M, Goldring J, Gopalan D, Heightman
- M, Hillman T, Howard L, Jacobs M, Jeetley PS, Kanagaratnam P, Kon OM, Lamb LE, Manisty CH,
- Mathurdas P, Mayet J, Negus R, Patel N, Pierce I, Russell G, Wolff A, Xue H, Kellman P, Moon JC,
- 18 Treibel TA, Cole GD, Fontana M. Patterns of myocardial injury in recovered troponin-positive COVID-
- 19 patients assessed by cardiovascular magnetic resonance. Eur Heart J. 2021:ehab075. doi:
- 20 10.1093/eurheartj/ehab075. Epub ahead of print.
- 21 35. Rajpal S, Tong MS, Borchers J, Zareba KM, Obarski TP, Simonetti OP, Daniels CJ. Cardiovascular
- 22 Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection. JAMA
- 23 Cardiol. 2021;6(1):116-118. doi: 10.1001/jamacardio.2020.4916.
- 24 36. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ,
- van Paassen J, Stals MAM, Huisman MV, Endeman H. Incidence of thrombotic complications in
- critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147. doi:
- 27 10.1016/j.thromres.2020.04.013.
- 28 37. Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, Jeanpierre E, Rauch A, Labreuche
- J, Susen S; Lille ICU Haemostasis COVID-19 Group. Pulmonary Embolism in Patients With COVID-

- 1 19: Awareness of an Increased Prevalence. Circulation. 2020;142(2):184-186. doi: 2 10.1161/CIRCULATIONAHA.120.047430.
- 38. Alvarez-Garcia J, Lee S, Gupta A, Cagliostro M, Joshi AA, Rivas-Lasarte M, Contreras J, Mitter SS,
 LaRocca G, Tlachi P, Brunjes D, Glicksberg BS, Levin MA, Nadkarni G, Fayad Z, Fuster V, Mancini
- 5 D, Lala A. Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19. J Am Coll
- 6 Cardiol. 2020 Nov 17;76(20):2334-2348. doi: 10.1016/j.jacc.2020.09.549.
- 7 39. Tomasoni D, Inciardi RM, Lombardi CM, Tedino C, Agostoni P, Ameri P, Barbieri L, Bellasi A,
- 8 Camporotondo R, Canale C, Carubelli V, Carugo S, Catagnano F, Dalla Vecchia LA, Danzi GB, Di
- Pasquale M, Gaudenzi M, Giovinazzo S, Gnecchi M, Iorio A, La Rovere MT, Leonardi S, Maccagni G,
- Mapelli M, Margonato D, Merlo M, Monzo L, Mortara A, Nuzzi V, Piepoli M, Porto I, Pozzi A, Sarullo
- F, Sinagra G, Volterrani M, Zaccone G, Guazzi M, Senni M, Metra M. Impact of heart failure on the
- 12 clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy
- multicentre study. Eur J Heart Fail. 2020;22(12):2238-2247. doi: 10.1002/ejhf.2052.
- 40. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, Tobin KA, Cerfolio RJ,
- Francois F, Horwitz LI. Factors associated with hospital admission and critical illness among 5279
- people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ.
- 17 2020;369:m1966. doi: 10.1136/bmj.m1966.
- 18 41. Mountantonakis SE, Saleh M, Fishbein J, Gandomi A, Lesser M, Chelico J, Gabriels J, Qiu M, Epstein
- 19 LM; Northwell COVID-19 Research Consortium. Atrial fibrillation is an independent predictor for in-
- hospital mortality in patients admitted with SARS-CoV-2 infection. Heart Rhythm. 2021:S1547-
- 21 5271(21)00040-0. doi: 10.1016/j.hrthm.2021.01.018.
- 42. Störk S, Handrock R, Jacob J, Walker J, Calado F, Lahoz R, Hupfer S, Klebs S. Epidemiology of heart
- failure in Germany: a retrospective database study. Clin Res Cardiol. 2017;106(11):913-922. doi:
- 24 10.1007/s00392-017-1137-7.
- 43. Ammar KA, Jacobsen SJ, Mahoney DW, Kors JA, Redfield MM, Burnett JC Jr, Rodeheffer RJ.
- Prevalence and prognostic significance of heart failure stages: application of the American College of
- 27 Cardiology/American Heart Association heart failure staging criteria in the community. Circulation.
- 28 2007;115(12):1563-70. doi: 10.1161/CIRCULATIONAHA.106.666818.
- 44. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA,
- Magnani JW, Ellinor PT, Seshadri S, Wolf PA, Vasan RS, Benjamin EJ, Levy D. 50 year trends in atrial

1 Tables

Table 1: Baseline characteristics	Overall	No pre-exis	sting cardiac	Pre-existing cardiac	
		disease		disease	
		≤65 years	>65 years	≤65 years	>65 years
Total	10481	4416	2870	599	2596
Age, years (%)*					
18 - 25	148 (1.4)	143 (3.2)	0 (0.0)	5 (0.8)	0 (0.0)
26 - 35	429 (4.1)	415 (9.4)	0 (0.0)	14 (2.3)	0 (0.0)
36 - 45	717 (6.8)	680 (15.4)	0 (0.0)	37 (6.2)	0 (0.0)
46 - 55	1503 (14.3)	1359 (30.8)	0 (0.0)	144 (24.0)	0 (0.0)
56 - 65	2218 (21.2)	1819 (41.2)	0 (0.0)	399 (66.6)	0 (0.0)
66 - 75	2346 (22.4)	0 (0.0)	1446 (50.4)	0 (0.0)	900 (34.7)
76 - 85	2247 (21.4)	0 (0.0)	1076 (37.5)	0 (0.0)	1171 (45.1)
>85	873 (8.3)	0 (0.0)	348 (12.1)	0 (0.0)	525 (20.2)
Sex, female (%)*	4051 (38.7)	1677 (38.0)	1283 (44.7)	168 (28.0)	923 (35.6)
Ethnicity (%)*					
Arab	458 (5.0)	278 (7.5)	90 (3.5)	39 (7.4)	51 (2.2)
Asian	518 (5.7)	332 (8.9)	74 (2.9)	58 (11.1)	54 (2.3)
Black	278 (3.0)	192 (5.2)	52 (2.0)	17 (3.2)	17 (0.7)
Latin-American	25 (0.3)	14 (0.4)	6 (0.2)	4 (0.8)	1 (0.0)
White	7606 (83.1)	2735 (73.5)	2277 (89.0)	395 (75.4)	2199 (93.5)
Other	269 (2.9)	170 (4.6)	59 (2.3)	11 (2.1)	29 (1.2)
BMI (kg/m ²)(%) *					
Underweight (<18.5)	125 (1.8)	22 (0.8)	65 (3.5)	10 (2.3)	28 (1.5)
Normal weight (18.5 – 24.9)	2095 (30.1)	732 (26.0)	670 (35.8)	103 (23.5)	590 (32.0)
Overweight (25.0 – 29.9)	2691 (38.6)	1093 (38.8)	697 (37.3)	167 (38.0)	734 (39.9)
Obese (30.0 – 34.9)	1372 (19.7)	615 (21.8)	302 (16.1)	101 (23.0)	354 (19.2)
Morbidly obese (> 34.9)	685 (9.8)	355 (12.6)	137 (7.3)	58 (13.2)	135 (7.3)
Cardiovascular risk factors (%)					
Diabetes*	2482 (24.0)	668 (15.4)	722 (25.5)	204 (34.5)	888 (34.7)
Hypertension*	4973 (48.4)	1207 (27.8)	1564 (55.8)	342 (58.7)	1860 (73.1)
Peripheral arterial disease*	442 (5.1)	41 (1.1)	117 (5.0)	28 (5.8)	256 (12.4)
Comorbidities (%)					
Chronic kidney disease*	1274 (12.3)	163 (3.7)	339 (12.0)	73 (12.4)	699 (27.4)
COPD*	994 (9.6)	168 (3.8)	342 (12.1)	64 (10.8)	420 (16.4)
Use cardiovascular drugs (%)	221 (210)	100 (010)	(====)	(1010)	120 (2011)
ACE-inhibitors*	1848 (18.1)	372 (8.7)	514 (18.3)	181 (30.9)	781 (30.6)
Aldosterone antagonist	390 (3.8)	28 (0.6)	52 (1.8)	49 (8.3)	261 (10.3)
	2003 (19.4)	` ′	` ′	273 (46.4)	` ′
Anti-platelet	. /	195 (4.5)	543 (19.1)	\ /	992 (38.9)
Angiotensin receptor blocker*	1340 (13.1)	300 (7.0)	407 (14.6)	102 (17.4)	531 (21.0)
Calcium-blocker	1658 (16.0)	394 (9.0)	503 (17.7)	127 (21.6)	634 (24.9)
Diuretic	2032 (19.7)	302 (6.9)	530 (18.7)	146 (24.9)	1054 (41.4)
Insulin	699 (6.7)	169 (3.8)	191 (6.7)	77 (13.0)	262 (10.2)
Lipid-lowering*	2978 (30.2)	491 (12.0)	804 (29.7)	322 (56.1)	1361 (55.0)
Oral anti-diabetic	1258 (12.0)	346 (7.8)	378 (13.2)	99 (16.6)	435 (16.8)

^{2 *} Variables included in the multiple imputation model

5 6

³ ACE = Angiotensin converting enzyme; BMI = Body Mass Index; COPD = Chronic Obstructive Pulmonary

⁴ Disease

Table 2: Complaints, vitals and laboratory values at admission stratified by pre-existing cardiac disease and age						
	Overall	No pre-existi disease	ng cardiac	Pre-existing disease	cardiac	
		≤65 years	>65 years	≤65 years	>65 years	
Total	10481	4416	2870	599	2596	
Admission						
Onset of symptoms to	6 [2 – 9]	6 [2 – 9]	5 [1 – 9]	6 [2 – 9]	4 [1 – 8]	
admission, days, median, [IQR]						
Complaints at admission (%)						
Anosmia	402 (4.1)	265 (6.5)	65 (2.5)	26 (4.5)	46 (1.9)	
Cough	5472 (56.4)	2510 (62.0)	1418 (53.5)	329 (57.5)	1215 (50.1)	
Dyspnea	5056 (52.6)	2163 (53.9)	1362 (51.9)	302 (53.1)	1229 (51.2)	
Fatigue	2777 (28.6)	1120 (27.6)	826 (31.2)	152 (26.6)	679 (28.0)	
Fever	5852 (60.3)	2628 (64.9)	1556 (58.8)	348 (60.8)	1320 (54.4)	
Gastrointestinal symptoms	2055 (21.2)	870 (21.5)	571 (21.6)	128 (22.4)	486 (20.0)	
Palpitations	117 (1.2)	34 (0.8)	31 (1.2)	12 (2.1)	40 (1.6)	
Sore throat	776 (8.0)	434 (10.7)	188 (7.1)	45 (7.9)	109 (4.5)	
Vitals at admission (%) Temperature (°C)*				 	+	
1	10 (0 6)	11 (0.4)	16 (0.0)	2 (0.7)	10 (1.0)	
< 35.1	49 (0.6)	11 (0.4)	16 (0.8)	3 (0.7)	19 (1.0)	
35.1 – 37.2 37.3 – 37.9	2821 (37.4)	1057 (34.5)	802 (38.0)	178 (40.2)	784 (40.9)	
	1698 (22.5)	702 (22.9)	458 (21.7)	97 (21.9)	441 (23.0)	
38.0 – 38.9	2030 (26.9)	849 (27.7)	575 (27.2)	115 (26.0)	491 (25.6)	
39.0 – 39.9	833 (11.0)	395 (12.9)	234 (11.1)	44 (9.9)	160 (8.3)	
> 39.9	109 (1.4)	53 (1.7)	27 (1.3)	6 (1.4)	23 (1.2)	
Respiratory rate (breaths/min) < 16	045 (12.0)	205 (11.0)	254 (11.7)	60 (13.0)	246 (12.4)	
16 – 21	945 (12.0) 3421 (43.4)	385 (11.8) 1432 (43.9)	254 (11.7) 933 (42.9)	216 (47.0)	246 (12.4) 840 (42.4)	
$\frac{10-21}{22-29}$	2370 (30.1)	942 (28.9)	682 (31.4)	125 (27.2)	621 (31.3)	
> 29	1145 (14.5)	505 (15.5)	305 (14.0)	59 (12.8)	276 (13.9)	
Heart rate (beats/min)	1113 (11.3)	303 (13.3)	303 (11.0)	37 (12.0)	270 (13.5)	
< 45	36 (0.4)	11 (0.3)	10 (0.4)	1 (0.2)	14 (0.6)	
45 – 59	218 (2.5)	52 (1.4)	59 (2.4)	14 (2.7)	93 (4.2)	
60 - 89	4617 (52.4)	1716 (46.9)	1370 (56.5)	265 (51.4)	1266 (57.1)	
90 – 119	3404 (38.6)	1660 (45.3)	860 (35.4)	207 (40.1)	677 (30.6)	
> 119	544 (6.2)	222 (6.1)	127 (5.2)	29 (5.6)	166 (7.5)	
Systolic blood pressure (mmHg)						
< 80	47 (0.6)	8 (0.3)	12 (0.6)	5 (1.1)	22 (1.1)	
80 – 99	349 (4.6)	104 (3.4)	102 (4.8)	30 (6.8)	113 (5.9)	
100 - 119	1648 (21.9)	702 (23.0)	408 (19.3)	109 (24.8)	429 (22.3)	
120 – 139	2764 (36.7)	1289 (42.2)	702 (33.2)	156 (35.5)	617 (32.1)	
140 – 179	2489 (33.0)	891 (29.1)	801 (37.8)	132 (30.1)	665 (34.6)	
> 179	240 (3.2)	63 (2.1)	92 (4.3)	7 (1.6)	78 (4.1)	
Diastolic blood pressure (mmHg)						
< 40	27 (0.4)	7 (0.2)	9 (0.4)	2 (0.5)	9 (0.5)	
40 – 59	821 (10.9)	178 (5.8)	267 (12.6)	58 (13.2)	318 (16.5)	
60 – 89	5399 (71.7)	2256 (73.9)	1519 (71.8)	316 (72.0)	1308 (68.1)	
90 – 109	1157 (15.4)	567 (18.6)	284 (13.4)	57 (13.0)	249 (13.0)	
> 109	125 (1.7)	45 (1.5)	36 (1.7)	6 (1.4)	38 (2.0)	
Oxygen saturation (%)*	(217)	15 (1.0)	()	- ()		
< 60	45 (0.6)	20 (0.6)	13 (0.6)	4 (0.9)	8 (0.4)	
60 – 69	38 (0.5)	16 (0.5)	10 (0.5)	2 (0.5)	10 (0.5)	
70 – 79	133 (1.8)	54 (1.8)	39 (1.8)	5 (1.1)	35 (1.8)	
	, ,	` ′	` ′	` ′	` ′	
80 - 89	853 (11.3)	286 (9.3)	286 (13.5)	51 (11.6)	230 (12.0)	

90 – 95	3156 (41.8)	1186 (38.5)	934 (44.1)	185 (42.0)	851 (44.4)
96 – 100	3331 (44.1)	1518 (49.3)	836 (39.5)	193 (43.9)	784 (40.9)
Laboratory values at admission					
(%)					
CRP (mg/L) *					
< 3	295 (4.0)	168 (5.5)	59 (2.8)	14 (3.4)	54 (3.0)
3 - 29	1518 (20.5)	701 (22.8)	350 (16.7)	90 (21.7)	377 (20.7)
30 - 69	1735 (23.4)	692 (22.5)	488 (23.3)	106 (25.5)	449 (24.7)
70 - 119	1458 (19.7)	554 (18.0)	447 (21.3)	80 (19.3)	377 (20.7)
120 – 179	1151 (15.5)	437 (14.2)	361 (17.2)	59 (14.2)	294 (16.2)
180 - 249	674 (9.1)	264 (8.6)	212 (10.1)	37 (8.9)	161 (8.9)
> 249	575 (7.8)	259 (8.4)	180 (8.6)	29 (7.0)	107 (5.9)
White blood cell count (x 10^9/L)					
*					
< 1.0	21 (0.3)	10 (0.3)	7 (0.3)	0 (0.0)	4 (0.2)
1.0 – 3.9	871 (11.8)	399 (13.0)	226 (10.8)	53 (12.6)	193 (10.7)
4.0 - 7.9	3922 (53.1)	1672 (54.3)	1076 (51.6)	220 (52.3)	954 (52.9)
8.0 - 11.9	1804 (24.4)	714 (23.2)	521 (25.0)	109 (25.9)	460 (25.5)
12.0 - 15.9	560 (7.6)	213 (6.9)	187 (9.0)	27 (6.4)	133 (7.4)
16.0 – 19.9	179 (2.4)	62 (2.0)	61 (2.9)	10 (2.4)	46 (2.6)
> 20	28 (0.4)	7 (0.2)	6 (0.3)	2 (0.5)	13 (0.7)
Lymphocyte count (x 10^9/L)*					
< 0.1	37 (0.6)	9 (0.4)	15 (0.9)	4 (1.3)	9 (0.6)
0.10 - 0.29	215 (3.7)	46 (2.0)	81 (4.8)	8 (2.5)	80 (5.5)
0.30 - 0.49	559 (9.7)	149 (6.5)	205 (12.2)	15 (4.7)	190 (13.1)
0.50 - 0.79	1501 (26.2)	519 (22.7)	480 (28.5)	78 (24.5)	424 (29.3)
0.80 - 1.49	2456 (42.8)	1102 (48.2)	657 (39.1)	143 (45.0)	554 (38.2)
1.50 - 2.99	874 (15.2)	421 (18.4)	218 (13.0)	67 (21.1)	168 (11.6)
> 3.0	94 (1.6)	41 (1.8)	26 (1.5)	3 (0.9)	24 (1.7)
Hemoglobin (mmol/L) *					
< 3.73	16 (0.2)	5 (0.2)	8 (0.4)	0 (0.0)	3 (0.2)
3.73 - 4.90	102 (1.4)	36 (1.2)	24 (1.2)	5 (1.2)	37 (2.1)
4.91 – 6.15	426 (5.9)	121 (4.1)	121 (6.0)	29 (7.2)	155 (8.8)
6.16 – 7.39	1234 (17.2)	391 (13.1)	381 (18.9)	65 (16.1)	397 (22.6)
7.4 - 9.25	4069 (56.8)	1740 (58.4)	1212 (60.0)	207 (51.2)	910 (51.7)
> 9.25	1314 (18.3)	685 (23.0)	274 (13.6)	98 (24.3)	257 (14.6)
Platelets (x 10^9/L)	()	(/	(/	(- /	- /
< 10	16 (0.2)	4 (0.1)	7 (0.4)	0 (0.0)	5 (0.3)
10 – 49	55 (0.8)	24 (0.8)	16 (0.9)	0 (0.0)	15 (0.9)
50 – 119		183 (6.4)	169 (9.0)	29 (7.4)	208 (12.6)
	1 209 (0.71		(- • - /	1 ()	===(1=:0)
120 – 449	589 (8.7) 5886 (87.0)	` ′	1614 (86.1)	348 (88.3)	1390 (83.9)
120 – 449 450 – 799	5886 (87.0) 217 (3.2)	2534 (89.2) 93 (3.3)	1614 (86.1) 69 (3.7)	348 (88.3) 17 (4.3)	1390 (83.9) 38 (2.3)

^{*} Variables included in the multiple imputation model

² CRP = C-Reactive Protein IQR = Interquartile Range

	Overall	No pre-existing cardiac disease		Pre-existing cardiac disease	
		≤65 years	>65 years	≤65 years	>65 years
Total	10481	4416	2870	599	2596
Admission					
Duration of hospitalization, days, median [IQR]	9 [5 – 19]	8 [4 – 17]	10 [5 – 20]	10 [5 – 20]	10 [5 – 20]
Admission to a critical care unit*	2655 (25.3)	1239 (28.1)	721 (25.1)	195 (32.6)	500 (19.3)
Duration of stay critical care unit, days, median [IQR]	13 [6 – 24]	13 [7 – 24]	13 [6 – 25]	13 [6 – 25]	12 [4 – 24]
Treatment					
Invasive ventilation	1996 (19.1)	932 (21.1)	558 (19.5)	146 (24.4)	360 (13.9)
Non-invasive ventilation	1189 (11.4)	569 (12.9)	320 (11.2)	82 (13.8)	218 (8.4)
ECMO	190 (1.8)	136 (3.1)	32 (1.1)	12 (2.0)	10 (0.4)
Complications (%)					
Cardiac					
Myocarditis	28 (0.3)	12 (0.3)	7 (0.3)	2 (0.3)	7 (0.3)
Myocardial infarction	60 (0.6)	8 (0.2)	18 (0.7)	7 (1.2)	27 (1.1)
Heart failure de novo	115 (1.2)	20 (0.5)	26 (1.0)	6 (1.0)	63 (2.5)
Thromboembolic	, ,				
Pulmonary embolism	420 (4.2)	197 (4.7)	139 (5.1)	23 (4.0)	61 (2.5)
Stroke	62 (0.6)	16 (0.4)	21 (0.8)	3 (0.5)	22 (0.9)
Venous thrombosis	89 (0.9)	46 (1.1)	27 (1.0)	2 (0.3)	14 (0.6)
Outcome (%)	` ′	<u> </u>	` ′	` ′	` '
Deceased*	2111 (20.1)	321 (7.3)	822 (28.6)	82 (13.7)	886 (34.1)

^{*} Variables included in the multiple imputation model

4

ECMO = Extracorporeal membrane oxygenation; IQR = Interquartile Range

Figure legends

- Figure 1: Associations (crude: top; age- and sex adjusted; center, multivariable adjusted; bottom) between any
- 3 history of cardiac disease, heart disease subtypes and in-hospital mortality.
- 4 Figure 2: Multivariable adjusted associations between any history of cardiac disease, heart disease subtypes and
- 5 in-hospital mortality in patients aged ≤65 (top) and >65 years (bottom). *p-value interaction heart disease subtype
- 6 and age. Patients with prior myocardial infarction are included in the coronary artery disease group.

7

1

Figure 1

In-hospital mortality


	,	RR (95% CI)	p-value
Crude Any history of cardiac disease Arrhythmia/conduction disorder Atrial fibrillation Coronary artery disease Myocardial infarction Heart failure NYHA I/II NYHA III/IV Valvular disease		1.93 [1.79 - 2.08] 1.87 [1.72 - 2.03] 1.92 [1.76 - 2.09] 1.65 [1.51 - 1.79] 1.52 [1.32 - 1.74] 2.01 [1.82 - 2.23] 1.65 [1.38 - 1.97] 2.47 [2.15 - 2.85] 1.76 [1.53 - 2.03]	<0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Age and sex adjusted Any history of cardiac disease Arrhythmia/conduction disorder Atrial fibrillation Coronary artery disease Myocardial infarction Heart failure NYHA I/II NYHA III/IV Valvular disease		1.12 [1.03 - 1.21] 1.12 [1.03 - 1.21] 1.15 [1.05 - 1.25] 1.08 [0.99 - 1.18] 1.04 [0.91 - 1.19] 1.28 [1.16 - 1.42] 1.05 [0.88 - 1.25] 1.56 [1.35 - 1.80] 1.14 [0.99 - 1.31]	0.01 <0.001 0.08 0.60 <0.001 0.58 <0.001
Multivariable adjusted Any history of cardiac disease Arrhythmia/conduction disorder Atrial fibrillation Coronary artery disease Myocardial infarction Heart failure NYHA I/II NYHA III/IV Valvular disease	1.0 1.5 2.0 RR (log-scale)	1.06 [0.98 - 1.15] 1.09 [1.00 - 1.19] 1.14 [1.04 - 1.24] 1.05 [0.96 - 1.14] 1.02 [0.89 - 1.17] 1.14 [1.02 - 1.27] 0.98 [0.83 - 1.17] 1.43 [1.22 - 1.68] 1.07 [0.93 - 1.24]	0.06 0.01 0.33 0.74 0.02 0.86 <0.001

9

10

Figure 2

In-hospital mortality



Disclosures

None.

3 4

1

Authors

5 Linschoten M¹, Uiil A², Schut A³, Jakob CEM^{4,5}, Romão LR^{6,7}, Bell RM⁸, McFarlane E⁹, Stecher M^{4,5}, Zondag AGM², van Iperen EPA¹⁰, Hermans-van Ast W¹⁰, Lea NC⁷, Schaap J^{3,11}, Jewbali LS^{12,13}, Smits PC¹⁴, Patel RS^{7,9}, 6 7 Aujayeb A¹⁵, Ripley DP¹⁶, Saxena M¹⁷, Spinner C^{5,18}, McCann GP¹⁹, Moss AJ¹⁹, Parker E¹⁹, Borgmann S²⁰, 8 Tessitore E²¹, Rieg S²², Kearney MT²³, Byrom-Goulthorp R²³, Hower M²⁴, Al-Ali AK²⁵, Alshehri AM²⁶, Alnafie 9 AN²⁷, Alshahrani M²⁸, Almubarak YA²⁹, Al-Muhanna FA³⁰, Al-Rubaish AM³⁰, Hanses F³¹, Shore AC³², Ball C³², Anning CM³², Rüthrich MM³³, Nierop PR³⁴, Vehreschild MJGT³⁵, Heymans SRB³⁶⁻³⁸, Henkens MTHM³⁶, Raafs 10 AG³⁶, Lanznaster J³⁹, Kopylov PY⁴⁰, Blagova OV⁴¹, Wille K⁴², Pinto YM⁴³, Offerhaus JA⁴³, Bleijendaal H^{43,44}, 11 12 Piepel C⁴⁵, ten Berg JM⁴⁶, Bor WL⁴⁶, Maarse M⁴⁶, Römmele C⁴⁷, Tio RA^{48,49}, Sturkenboom NH⁴⁸, Tometten L⁵⁰, 13 den Uil CA^{12,13}, Scholte NTB¹², Groenendijk AL⁵¹, Dolff S⁵², Zijlstra LE⁵³, Hilt AD⁵³, von Bergwelt-Baildon M⁵⁴-14 ⁵⁶, Groenemeijer BE⁵⁷, Merle U⁵⁸, van der Zee PM⁵⁹, van Beek EA⁵⁹, Rothfuss K⁶⁰, Tjong FVY^{43,61,62}, van der Lingen ACJ⁶¹, Kolk MZH⁴³, Isberner N⁶³, Monraats PS⁶⁴, Magro M⁶⁴, Hermans WRM⁶⁴, Kochanek M^{65,66}, Captur 15 16 G^{9,67}, Thomson RJ^{68,69}, Nadalin S⁷⁰, Linssen GCM⁷¹, Veneman T⁷², Zaal R⁷³, Degenhardt C⁷⁴, Martens FMAC⁷⁵, 17 Badings EA⁷⁵, Strauss R⁷⁶, Zaman AG⁷⁷, Alkhalil M⁷⁸, Grüner B⁷⁹, Haerkens-Arends HE⁸⁰, Eberwein L⁸¹, Dark 18 P⁸², Lomas D⁸², Lyons C⁸², vom Dahl J⁸³, Verschure DO⁸⁴, Hellwig K⁸⁵, Mosterd A⁸⁶, Rauschning D⁸⁷, van der Heijden DJ⁸⁸, Neufang M⁸⁹, van Hessen M⁹⁰, Raichle C⁹¹, Montagna L⁹², Mazzilli SG⁹³, Bianco M⁹⁴, Schultheis 19 20 B⁹⁵, Shafiee A⁹⁶, Hedayat B⁹⁷, Saneei E⁹⁸, Porhosseini H⁹⁹, Jensen B¹⁰⁰, Gabriel L¹⁰¹, Er AG¹⁰², Kietselaer 21 BLJH¹⁰³, Schubert J¹⁰⁴, Timmermans P Jr¹⁰⁵, Messiaen P^{106,107}, Friedrichs A¹⁰⁸, van den Brink FS¹⁰⁹, Woudstra 22 P¹⁰⁹, Trauth J¹¹⁰, Ribeiro MIA¹¹¹, de With K¹¹², van der Linden MMJM¹¹³, Kielstein JT¹¹⁴, Macías Ruiz R¹¹⁵, 23 Guggemos W¹¹⁶, Hellou E¹¹⁷, Markart P¹¹⁸, van Kesteren HAM¹¹⁹, Heigener D¹²⁰, de Vries JK¹²¹, Stieglitz S¹²², Baltazar Ferreira J¹²³, Voigt J¹²⁴, van de Watering DJ¹²⁵, Milovanovic M¹²⁶, Redón J^{127,128}, Forner MJ^{127,128}, Rüddel 24 25 J¹²⁹, Wu KW¹³⁰, Nattermann J¹³¹, Veldhuis LI¹³², Westendorp ICD¹³³, Riedel C¹³⁴, Kwakkel-van Erp JM¹³⁵, van Ierssel S¹³⁶, van Craenenbroeck EM¹³⁷, Walter L¹³⁸, de Sutter J^{139,140}, Worm M¹⁴¹, Drost JT¹⁴², Kaplan R¹⁴², 26 Moriarty A¹⁴³, Salah R¹⁴⁴, Charlotte N¹⁴⁵, van Boxem AJM¹⁴⁶, Dorman HGR¹⁴⁷, Reidinga AC¹⁴⁸, van der Meer 27 P¹⁴⁹, Wierda E⁶², van Veen HPAA¹⁵⁰, Delsing CE¹⁵¹, Meijs MFL¹⁵², van de Wal RMA¹⁵³, Weytjens C¹⁵⁴, 28 29 Hermanides RS¹⁵⁵, Emans ME¹⁵⁶, al-Windy NYY¹⁵⁷, Koning AMH¹⁵⁸, Schellings DAAM¹⁵⁹, Anthonio RL¹⁶⁰, Bucciarelli-Ducci C¹⁶¹, Caputo M^{162,163}, Westendorp PHM¹⁶⁴, Kuijper AFM¹⁶⁵, van Ofwegen-Hanekamp CEE¹⁶⁶, 30

- $1 \qquad \text{Persoon AM}^{167}, \, \text{Seelig J}^{168}, \, \text{van der Harst P}^1, \, \text{Siebelink HJ}^{53}, \, \text{van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{Van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{Van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{Van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{Van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{Van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{Van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{Van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{Van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{Van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{Van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{Van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{Van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{Van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{Van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram M}^2, \, \text{Van Smeden M}^2, \, \text{Williams S}^{169}, \, \text{Pilgram L}^{170}, \, \text{Van Smeden M}^2, \, \text{Van Smeden M}^2$
- 2 Gilst WH¹⁷¹, Tieleman RG¹⁷², Williams B^{6,9}, Asselbergs FW^{1,7,9}.

3

4

Collaborators

- 5 Alling TE¹, Handgraaf S²¹, Gognieva DG⁴⁰, Mesitskaya DF¹⁷³, van der Graaf M¹², Ruiter AH¹², Pölkerman BC⁵⁷,
- 6 Jansen SE⁵⁷, Selder JL^{43,61}, Pieterse-Rots A⁷¹, Kuipers-Elferink L⁷¹, van der Sluis A⁷⁵, van Eck JWM⁸⁰, Gevers
- 7 RMM⁸⁰, van Dalen DH⁸⁰, Lensink E⁸⁴, Bunschoten P⁸⁶, van Doorn JL⁸⁶, Knufman N⁸⁸, van Marrewijk V⁸⁸,
- 8 Broekman M⁹⁰, Bos M⁹⁰, Perrelli MG⁹², Biolé CA⁹², Hosseini K⁹⁷, Tajdini M¹⁷⁴, Domange JD¹⁰¹, Dormal FD¹⁰¹,
- 9 Jourdan JD¹⁰¹, Kleikers P¹⁰³, Hessels-Linnemeijer BM¹⁰³, Dekimpe E¹⁰⁵, Janssen A¹⁰⁵, Sousa AIC¹¹¹, Cardoso
- 10 NM¹¹¹, Tercedor Sánchez L¹¹⁵, Bermúdez Jiménes J¹¹⁵, Koole BAS¹¹⁹, Huisman J¹¹⁹, Kui KK¹²¹, Bruinsma S¹²¹,
- 11 Kievit CM¹³⁰, van Kempen MJ¹³⁰, Melein AJ¹³³, Koole MAC¹³³, van Poppel A¹³⁵, van Meerbeeck JP¹³⁵, Vlieghe
- 12 E¹³⁶, ten Kate GL¹³⁶, Heidbuchel H¹³⁷, van de Heyning CM¹³⁷ Willems AM¹³⁹, Meijer EJ¹⁴², Habib A¹⁷⁵,
- 13 Elshinawy K¹⁷⁵, Vial H¹⁷⁶, Grangeon S¹⁷⁶, Wils AM¹⁴⁷, Jacobs TC¹⁴⁷, Vreugdenhil P¹⁷², Hendriks-van Woerden
- 14 M¹⁷², van Aken K¹⁴⁹, Hamilton K¹⁴⁹, van Nes CPM⁶², Vonkeman HE¹⁷⁷, Haenen NA¹⁵³, de Bruijn EAW¹⁷⁸,
- Lemoine I¹⁵⁴, Guclu A¹⁵⁵, Dunnink A¹⁵⁵, den Boer-Penning P¹⁵⁶, Zoet-Nugteren SK¹⁵⁶, Reitsma MJ¹⁵⁸, Broeyer
- 16 FJF¹⁷⁹, Drost IMJ¹⁵⁹, Reinders S¹⁵⁹, van der Kooi SE¹⁶⁰, Paris FMA¹⁶⁰, Bayraktar-Verver ECE¹⁶⁵, Bosch L¹⁶⁶,
- 17 Bontje M¹⁶⁶, Pisters R¹⁶⁸, de Vries TAC¹⁶⁸.

18

19

Affiliations

- 20 1. Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, University of
- 21 Utrecht, Utrecht, the Netherlands
- 22 2. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University,
- 23 Utrecht, the Netherlands
- 24 3. The Dutch Network for Cardiovascular Research (WCN), Utrecht the Netherlands
- 4. Department I for Internal Medicine, University Hospital of Cologne, University of Cologne, Cologne, Germany
- 26 5. German Center for Infection Research (DZIF), Brunswick, Germany
- 27 6. National Institute for Health University College London Hospitals, London Research Biomedical Research
- 28 Centre, United Kingdom
- 29 7. Health Data Research UK and Institute of Health Informatics, University College London, London, United
- 30 Kingdom

- 8. The Hatter Cardiovascular Institute, University College London, London, United Kingdom
- 9. Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London,
- 3 London, United Kingdom
- 4 10. Durrer Center, Netherlands Heart Institute, Utrecht, the Netherlands
- 5 11. Department of Cardiology, Amphia Hospital, the Netherlands
- 6 12. Department of Cardiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands
- 7 13. Department of Intensive Care, Erasmus MC University Medical Center, Rotterdam, the Netherlands
- 8 14. Department of Cardiology, Maasstad Hospital, Rotterdam, the Netherlands
- 9 15. Department of Respiratory and Acute Medicine, Northumbria HealthCare NHS Foundation Trust, Newcastle,
- 10 United Kingdom
- 16. Department of Cardiology, Northumbria HealthCare NHS Foundation Trust, Newcastle, United Kingdom
- 12 17. Barts NIHR Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of
- 13 London, United Kingdom
- 18. School of Medicine, Technical University of Munich, Department of Internal Medicine II, University
- 15 Hospital rechts der Isar, Munich, Germany
- 19. Department of Cardiovascular Sciences, University of Leicester and Cardiovascular Theme, NIHR Leicester
- 17 Biomedical Research Centre, Glenfield Hospital, Leicester, United Kingdom
- 18 20. Department of Infectious Diseases and Infection Control, Ingolstadt Hospital, Ingolstadt, Germany
- 19 21. Department of Cardiology, University Hospital of Geneva, Geneva, Switzerland
- 20 22. Internal Medicine II, Department of Infectious Diseases, Freiburg University Hospital, Freiburg, Germany
- 21 23. Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom
- 24. Clinic for Pneumology, Infectiology, Internal Medicine and Intensive Care, Hospital Dortmund gGmbH,
- 23 Dortmund, Germany
- 24 25. Department of Clinical Biochemistry, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal
- 25 University, Alkhobar, Saudi Arabia
- 26. Department of Cardiology, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University,
- 27 Alkhobar, Saudi Arabia
- 28 27. Department of Pathology, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University,
- 29 Alkhobar, Saudi Arabia

- 1 28. Department of Emergency Medicine, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal
- 2 University, Alkhobar, Saudi Arabia
- 3 29. Department of Critical Care, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University,
- 4 Alkhobar, Saudi Arabia
- 5 30. Department of Internal Medicine, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal
- 6 University, Alkhobar, Saudi Arabia
- 7 31. Emergency Department, University Hospital Regensburg, Regensburg, Germany
- 8 32. NIHR Exeter Clinical Research Facility, Royal Devon and Exeter Hospital and University of Exeter College
- 9 of Medicine & Health, Exeter, United Kingdom
- 10 33. Department of Internal Medicine II, Hematology and Medical Oncology, University Hospital Jena, Jena,
- 11 Germany
- 12 34. Department of Cardiology, Franciscus Gasthuis, Rotterdam, the Netherlands
- 13 35. Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University
- 14 Frankfurt, Frankfurt am Main, Germany
- 15 36. Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University
- Medical Center, Maastricht, the Netherlands
- 17 37. Department of Cardiovascular Sciences, Centre for Molecular and Vascular Biology, KU Leuven, Belgium
- 18 38. The Netherlands Heart Institute, NL-HI, Utrecht, The Netherlands
- 19 39. Department of Internal Medicine II, Passau Hospital, Passau, Germany
- 40. World-Class Research Center Digital biodesign and personalized healthcare, I.M. Sechenov First Moscow
- 21 State Medical University, Sechenov University, Moscow, Russia
- 41. Department of Faculty Therapy No. 1 of N.V. Sklifosovsky Institute for Clinical Medicine, I.M. Sechenov
- First Moscow State Medical University, Sechenov University, Moscow, Russia
- 42. University of Bochum, University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care,
- 25 Minden, Germany
- 26 43. Amsterdam University Medical Center, University of Amsterdam, Heart Center; Department of Clinical and
- 27 Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands
- 28 44. Amsterdam University Medical Center, University of Amsterdam, Department of Clinical Epidemiology,
- 29 Biostatistics & Bioinformatics, Amsterdam, the Netherlands
- 30 45. Klinikum Bremen-Mitte, Department of Internal Medicine I, Bremen, Germany

- 1 46. Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands
- 2 47. Department of Gastroenterology, University Hospital Augsburg, Augsburg, Germany
- 3 48. Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands
- 4 49. Department of Educational Development and Research in the Faculty of Health, Medicine and Life Sciences,
- 5 Catharina Hospital, Eindhoven, the Netherlands
- 6 50. Department of Gastroenterology and Infectiology, Hospital Ernst-von-Bergmann, Potsdam, Germany
- 7 51. Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center,
- 8 Rotterdam, the Netherlands
- 9 52. Department of Infectious Diseases, University Hospital Essen, University Duisburg Essen, Essen, Germany
- 10 53. Department of Cardiology, HeartLungCenter, Leiden University Medical Center, Leiden, the Netherlands
- 11 54. Department of Internal Medicine III, Ludwig Maximilians University, Munich, Germany
- 12 55. German Cancer Consortium (DKTK), partner site Munich, Munich, Germany
- 13 56. Bavarian Center for Cancer Research (BZKF), Munich, Germany
- 14 57. Department of Cardiology, Gelre Hospital Apeldoorn, Apeldoorn, the Netherlands
- 15 58. Department of Gastroenterology and Infectiology, Heidelberg University Hospital, Heidelberg, Germany
- 16 59. Department of Cardiology, St. Jansdal Hospital, Harderwijk, the Netherlands
- 17 60. Robert-Bosch Hospital, Department of Gastroenterology, Hepatology and Endocrinology, Stuttgart, Germany
- 18 61. Department of Cardiology, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam,
- the Netherlands
- 20 62. Department of Cardiology, Dijklander Hospital, Hoorn, the Netherlands
- 21 63. Department of Internal Medicine II, Division of Infectious Diseases, University Hospital Würzburg,
- Würzburg, Germany
- 23 64. Department of Cardiology, Elizabeth-TweeSteden Hospital, Tilburg, the Netherlands
- 24 65. Division of Infectious Diseases, Department I of Internal Medicine, University Hospital of Cologne,
- 25 University of Cologne, Cologne, Germany
- 26 66. German Center for Infection Research, Partner Site Bonn-Cologne, Cologne, Germany
- 27 67. Royal Free London NHS Foundation Trust, London, United Kingdom
- 28 68. William Harvey Research Institute, Queen Mary University of London, United Kingdom
- 29 69. Department of Intensive Care Medicine, Royal Free Hospital, Royal Free London NHS Foundation Trust,
- 30 London, United Kingdom

- 1 70. Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany
- 2 71. Department of Cardiology, Hospital Group Twente, Almelo, the Netherlands
- 3 72. Department of Intensive Care, Hospital Group Twente, Almelo, the Netherlands
- 4 73. Department of Pulmonology, Hospital Group Twente, Almelo, the Netherlands
- 5 74. Municipal Hospital Karlsruhe, Karlsruhe, Germany
- 6 75. Department of Cardiology, Deventer Hospital, Deventer, the Netherlands
- 7 76. Medical Clinic I, University Hospital Erlangen, Erlangen, Germany
- 8 77. Department of Cardiology, Freeman Hospital and Newcastle University, Newcastle upon Tyne NHS
- 9 Foundation Trust, United Kingdom
- 10 78. Department of Cardiothoracic Services, Freeman Hospital and Newcastle University, Newcastle upon Tyne
- 11 NHS Foundation Trust, United Kingdom
- 12 79. University Hospital Ulm, Division of Infectious Diseases, Clinic of Internal Medicine III
- 13 80. Department of Cardiology, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands
- 14 81. 4th Department of Internal Medicine, Hospital Leverkusen gGmbH, Leverkusen, Germany
- 15 82. Intensive Care Department, Salford Royal NHS Foundation Trust, Salford, United Kingdom
- 16 83. Division of Cardiology, Hospital Maria Hilf Mönchengladbach, Mönchengladbach, Germany
- 17 84. Department of Cardiology, Zaans Medical Center, Zaandam, The Netherlands
- 18 85. Department of Neurology, Katholisches Klinikum Bochum, Ruhr University Bochum, Bochum, Germany
- 19 86. Department of Cardiology, Meander Medical Center, Amersfoort, the Netherlands
- 20 87. Bundeswehr Central Hospital, Koblenz, Germany
- 21 88. Department of Cardiology, Haaglanden Medical Center, the Hague, the Netherlands
- 22 89. Evangelical City Hospital Saarbrücken, Saarbrücken, Germany
- 23 90. Department of Cardiology, Groene Hart Hospital, Gouda, the Netherlands
- 24 91. Tropical Clinic Paul-Lechler Hospital Tübingen, Tübingen, Germany
- 25 92. Department of Cardiology, A.O.U. San Luigi Gonzaga, Orbassano, Turin, Italy
- 26 93. Electrophysiology Unit, Department of Cardiology, A.O.U. San Luigi Gonzaga, Orbassano, Turin, Italy
- 27 94. Intensive Coronary Care Unit, Department of Cardiology, A.O.U. San Luigi Gonzaga, Orbassano, Turin, Italy
- 28 95. Department of Hematology and Oncology, Marien Hospital Herne, University of Bochum, Herne, Germany
- 29 96. Department of Cardiovascular Research, Tehran Heart Center, Cardiovascular Diseases Research Institute,
- 30 Tehran University of Medical Sciences, Tehran, Iran

- 1 97. Department of Cardiology, Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran
- 2 University of Medical Sciences, Tehran, Iran
- 3 98. Department of Nursing, Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University
- 4 of Medical Sciences, Tehran, Iran
- 5 99. Department of Interventional Cardiology, Tehran Heart Center, Cardiovascular Diseases Research Institute,
- 6 Tehran University of Medical Sciences, Tehran, Iran
- 7 100. Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf,
- 8 Heinrich-Heine-University, Düsseldorf, Germany
- 9 101. Department of Cardiology, CHU UCL Namur site Godinne, Université Catholique de Louvain, Yvoir,
- 10 Belgium
- 102. Department of Infectious Diseases and Clinical Microbiology, Hacettepe University School of Medicine,
- 12 Ankara, Turkey
- 13 103. Department of Cardiology, Zuyderland Medical Center, Heerlen, the Netherlands
- 14 104. Department of Internal Medicine, Hematology and Oncology, Elbland Hospital Riesa, Riesa, Germany
- 15 105. Department of Cardiology, Heart Center Hasselt, Jessa Hospital, Hasselt, Belgium
- 16 106. Department of Infectious Diseases & Immunity, Jessa Hospital, Hasselt, Belgium
- 17 107. Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium
- 18 108. Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Kiel, Germany
- 19 109. Department of Cardiology, Medical Center Leeuwarden (MCL), Leeuwarden, the Netherlands
- 20 110. Department of Medicine II, Section of Infectious Diseases, Justus-Liebig-University Giessen, Germany,
- 21 member of the German Lung Center (DZL)
- 22 111. Intensive Care Unit, Hospital do Espírito Santo, Évora, Portugal
- 23 112. Division of Infectious Diseases, University Hospital Carl Gustav Carus, Technical University of Dresden,
- 24 Dresden, Germany
- 25 113. Department of Cardiology, Franciscus Vlietland, Schiedam, The Netherlands
- 26 114. Medical Clinic V, Nephrology, Rheumatology, Blood Purification, Academic Teaching Hospital
- 27 Braunschweig, Braunschweig, Germany
- 28 115. Arrhythmias Unit, Department of Cardiology, Hospital Universitario Virgen de las Nieves, Granada, Spain
- 29 116. Munich Clinic Schwabing, Munich, Germany
- 30 117. Department of Cardiology, E.M.M.S Hospital, Nazareth, Israel

- 1 118. Section of Fibrotic Lung Diseases, University Hospital Giessen and Marburg, Giessen Campus, Justus
- 2 Liebig University Giessen, University of Giessen Marburg Lung Center, as well as the Fulda Campus of the
- 3 Medical University of Marburg, Med. Clinic V, Member of German Center for Lung Research Giessen,
- 4 Germany
- 5 119. Department of Cardiology, Admiraal de Ruyter Hospital, Goes, the Netherlands
- 6 120. Agaplesion Diaconia Hospial Rotenburg, Rotenburg, Germany
- 7 121. Department of Internal Medicine, Antonius Hospital, Sneek, the Netherlands
- 8 122. Department of Pneumology, Allergy, Sleep and Intensive Care Medicine, Petrus Hospital Wuppertal,
- 9 University of Witten-Herdecke, Wuppertal, Germany
- 10 123. Department of Cardiology, Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal
- 11 124. St. Josef Hospital Kupferdreh, Essen, Germany
- 12 125. Department of Cardiology, Albert Schweitzer Hospital, Dordrecht, the Netherlands
- 13 126. Malteser Hospital St. Franziskus-Hospital Flensburg, Flensburg, Germany
- 14 127. Department of Internal Medicine, Clinic University Hospital, INCLIVA Health Research Institute, Valencia,
- 15 Spain
- 16 128. Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain
- 17 129. Sophien- and Hufeland Clinic Weimar, Weimar, Germany
- 18 130. Department of Cardiology, van Weel-Bethesda Hospital, Dirksland, the Netherlands
- 19 131. Department of Internal Medicine I, Department of Gastroenterology, Hepatology, Nephrology, Infectiology,
- 20 Endocrinology and Diabetology, University Hospital Bonn, Bonn, Germany
- 21 132. Department of Intensive Care, Rode Kruis Hospital, Beverwijk, the Netherlands
- 22 133. Department of Cardiology, Rode Kruis Hospital, Beverwijk, the Netherlands
- 23 134. Helios Hospital Pirna, Pirna, Germany
- 24 135. Department of Pulmonology, Antwerp University Hospital, Edegem, Belgium
- 25 136. Department of General Internal Medicine, Infectious Diseases and Tropical Medicine, Antwerp University
- Hospital, Edegem, Belgium
- 27 137. Department of Cardiology, Antwerp University Hospital, Edegem, Belgium
- 28 138. Hospital St. Joseph-Stift Dresden, Dresden, Germany
- 29 139. Department of Cardiology, AZ Maria Middelares, Ghent, Belgium
- 30 140. Department of Internal Medicine, Ghent University, Ghent, Belgium

- 1 141. Oberlausitz Hospital, Germany
- 2 142. Department of Cardiology, Saxenburgh Medical Center, Hardenberg, the Netherlands
- 3 143. Craigavon Area Hospital, Southern Care & Social Care Trust Hospitals, Portadown, Northern Ireland
- 4 144. Benha Faculty of Medicine, Benha, Egypt
- 5 145. Department of Cardiology, SSR Val Rosay, Saint Didier au Mont d'Or, France
- 6 146. Department of Pulmonology, Bravis Hospital, Roosendaal, the Netherlands
- 7 147. Department of Cardiology, Bravis Hospital, Roosendaal, the Netherlands
- 8 148. Department of Intensive Care, Martini Hospital, Groningen, the Netherlands
- 9 149. Department of Cardiology, LangeLand Hospital, Zoetermeer, the Netherlands
- 10 150. Department of Pulmonology, Medisch Spectrum Twente, Enschede, the Netherlands
- 11 151. Derpartment of Internal Medicine and Infectious Diseases, Medisch Spectrum Twente, Enschede, the
- 12 Netherlands
- 13 152. Department of Cardiology, Thorax Center Twente, Medisch Spectrum Twente, Enschede, the Netherlands
- 14 153. Department of Cardiology, Bernhoven Hospital, Uden, the Netherlands
- 15 154. Department of Cardiology, CHVZ, University Hospital Brussels, Jette, Belgium
- 16 155. Department of Cardiology, Isala Hospital, Zwolle, the Netherlands
- 17 156. Department of Cardiology, Ikazia Hospital, Rotterdam, the Netherlands
- 18 157. Department of Cardiology, Gelre Hospital Zutphen, Zutphen, the Netherlands
- 19 158. Department of Gynecology, Amstelland Hospital, Amstelveen, the Netherlands
- 20 159. Department of Cardiology, Slingeland Hospital Doetinchem, the Netherlands
- 21 160. Department of Cardiology, Treant Zorggroep, Emmen, the Netherlands
- 22 161. NIHR Bristol Cardiovascular Biomedical Research Centre, Cardiac Magnetic Resonance Department,
- 23 Bristol Heart Institute, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
- 24 162. University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
- 25 163. Bristol Medical School, University of Bristol, Bristol, United Kingdom
- 26 164. Department of Cardiology, Beatrix Hospital, Gorinchem, the Netherlands
- 27 165. Department of Cardiology, Spaarne Gasthuis, Haarlem, the Netherlands
- 28 166. Department of Cardiology, Diakonessenhuis, Utrecht, the Netherlands
- 29 167. Department of Pulmonology, Diakonessenhuis, Utrecht, the Netherlands
- 30 168. Department of Cardiology, Rijnstate Hospital, Arnhem, the Netherlands

- 1 169. Barts Life Sciences, Barts Health NHS Trust, London, United Kingdom
- 2 170. Department of Internal Medicine, Hematology and Oncology, Goethe University Frankfurt, Frankfurt,
- 3 Germany
- 4 171. Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands
- 5 172. Department of Cardiology, Martini Hospital, Groningen, the Netherlands
- 6 173. Department of Cardiology, Functional and and Ultrasound Diagnostics of N.V. Sklifosovsky Institute for
- 7 Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Sechenov University, Moscow, Russia
- 8 174. Department of Emergency, Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran
- 9 University of Medical Sciences, Tehran, Iran
- 10 175. Department of Cardiology, One Day Surgery Hospital, Cairo, Egypt
- 11 176. COVID-19 Unit, SSR Val Rosay, Saint Didier au Mont d'Or, France
- 12 177. Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, the
- 13 Netherlands
- 14 178. Research Department, Bernhoven Hospital, Uden, the Netherlands
- 15 179. Department of Cardiology, Amstelland Hospital, Amstelveen, the Netherlands